BMS-214662 (mesylate)
BMS-214662 mesylate is a potent and selective farnesyl transferase inhibitor with an IC50 of 1.35 nM. BMS-214662 mesylate exhibits potent antitumor activity and can be utilized in cancer research[1].
Product Specifications
CAS Number
474010-58-7
UNSPSC
12352005
Target
Farnesyl Transferase
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Smiles
CS(=O)(O)=O.O=S(N(CC1=CC(C#N)=CC=C1N(C2)CC3=CN=CN3)[C@@H]2CC4=CC=CC=C4)(C5=CC=CS5)=O
Molecular Formula
C26H27N5O5S3
Molecular Weight
585.72
References & Citations
[1]Hunt JT, et al. Discovery of (R) -7-cyano-2,3,4, 5-tetrahydro-1- (1H-imidazol-4-ylmethyl) -3- (phenylmethyl) -4- (2-thienylsulfonyl) -1H-1,4-benzodiazepine (BMS-214662), a farnesyltransferase inhibitor with potent preclinical antitumor activity. J Med Chem. 2000 Oct 5;43 (20) :3587-95.|[2]Rose WC, et al. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor. Cancer Res. 2001 Oct 15;61 (20) :7507-17.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
